The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 13 October 2026, authorised Onswik (insulin efsitora alfa) for the treatment of type 2 diabetes mellitus in adults.
This new long-acting basal insulin is administered via injection once weekly. For some adults with type 2 diabetes, this could reduce the number of injections needed from up to 365 a year to 52.
Julian Beach, MHRA Executive Director of Healthcare Quality and Access, stated that the authorisation followed a rigorous assessment of available evidence. Clinical trial data indicated that once-weekly insulin efsitora alfa provided glycaemic control comparable to once-daily basal insulin treatments.
The National Institute for Health and Care Excellence (NICE) has also published final draft guidance recommending insulin efsitora alfa as an option for certain adults with type 2 diabetes, subject to MHRA licensing.
The most common adverse reaction reported with insulin efsitora alfa is hypoglycaemia, or low blood sugar.